tbuckley/cabot-search huggingface dataset:
Long-Term Exposure to Low-Level PM2.5 and Mortality: Investigation of Heterogeneity by Harmonizing Analyses in Large Cohort Studies in Canada, United States, and Europe
Authors: Jie Chen, Danielle Braun, Tanya Christidis, Michael Cork, Sophia Rodopoulou, Evangelia Samoli, Massimo Stafoggia, Kathrin Wolf, Xiao Wu, Weiran Yuchi, Zorana J. Andersen, Richard Atkinson, Mariska Bauwelinck, Kees de Hoogh, Nicole A.H. Janssen, Klea Katsouyanni, Jochem O. Klompmaker, Doris Tove Kristoffersen, Youn-Hee Lim, Bente Oftedal, Maciej Strak, Danielle Vienneau, Jiawei Zhang, Richard T. Burnett, Gerard Hoek, Francesca Dominici, Michael Brauer, Bert Brunekreef
Journal: Environmental Health Perspectives (2023)

Studies across the globe generally reported increased mortality risks associated with particulate matter with aerodynamic diameter ≤2.5μm (PM2.5) exposure with large heterogeneity in the magnitude of reported associations and the shape of concentration-response functions (CRFs). We aimed to evaluate the impact of key study design factors (including confounders, applied exposure model, population age, and outcome definition) on PM2.5 effect estimates by harmonizing analyses on three previously published large studies in Canada [Mortality-Air Pollution Associations in Low Exposure Environments (MAPLE), 1991–2016], the United States (Medicare, 2000–2016), and Europe [Effects of Low-Level Air Pollution: A Study in Europe (ELAPSE), 2000–2016] as much as possible.
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
Authors: Yan Wang, Shengjie Jin, Qiqi Zhuang, Na Liu, Ruyi Chen, Sofia Abdulkadir Adam, Jie Jin, Jie Sun
Journal: MedComm (2023)

Abstract Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft‐versus‐host disease and cytokine release syndrome, therapy resistance, limited sources, as well as high cost, limited the application of CAR T cells. Recently, CAR natural killer (NK) cells have been pursued as the effector cells for adoptive immunotherapy for their attractive merits of strong intrinsic antitumor activity and relatively mild side effects. Additionally, CAR NK cells can be available from various sources and do not require strict human leukocyte antigen matching, which suggests them as promising “off‐the‐shelf” products for clinical application. Although the use of CAR NK cells is restrained by the limited proliferation and impaired efficiency within the immunosuppressive tumor microenvironment, further investigation in optimizing CAR structure and combination therapies will overcome these challenges. This review will summarize the advancement of CAR NK cells, CAR NK cell manufacture, the clinical outcomes of CAR NK therapy, the challenges in the field, and prospective solutions. Besides, we will discuss the emerging application of other immune cells for CAR engineering. Collectively, this comprehensive review will provide a valuable and informative summary of current progress and evaluate challenges and future opportunities of CAR NK cells in tumor treatment.
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
Authors: Matthew H G Katz, Gina R Petroni, Todd Bauer, Matthew J Reilley, Brian M Wolpin, Chee-Chee Stucky, Tanios S Bekaii-Saab, Rawad Elias, Nipun Merchant, Andressa Dias Costa, Patrick Lenehan, Victoire Cardot-Ruffino, Scott Rodig, Kathleen Pfaff, Stephanie K Dougan, Jonathan Andrew Nowak, Gauri R Varadhachary, Craig L Slingluff, Osama Rahma
Journal: Journal for ImmunoTherapy of Cancer (2023)

Pancreatic ductal adenocarcinoma (PDAC) is a challenging target for immunotherapy because it has an immunosuppressive tumor microenvironment. Neoadjuvant chemoradiotherapy can increase tumor-infiltrating lymphocyte (TIL) density, which may predict overall survival (OS). We hypothesized that adding programmed cell death protein 1 (PD-1) blockade to chemoradiotherapy would be well tolerated and increase TILs among patients with localized PDAC.
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study
Authors: Jacoline E C Bromberg, Samar Issa, Bronno van der Holt, Matthijs van der Meulen, Linda Dirven, Monique C Minnema, Tatjana Seute, Marc Durian, Gavin Cull, Marjolein W M van der Poel, Wendy B C Stevens, Josee M Zijlstra, Dieta Brandsma, Marcel Nijland, Kylie D Mason, Aart Beeker, Martine C J Abrahamse-Testroote, Martin J van den Bent, Daphne de Jong, Jeanette K Doorduijn
Journal: Neuro-Oncology (2023)

Abstract Background Studies on the efficacy of rituximab in primary CNS lymphoma (PCNSL) reported conflicting results. Our international randomized phase 3 study showed that the addition of rituximab to high-dose methotrexate, BCNU, teniposide, and prednisolone (MBVP) in PCNSL was not efficacious in the short term. Here we present long-term results after a median follow-up of 82.3 months. Methods One hundred and ninety-nine eligible newly diagnosed, nonimmunocompromised patients with PCNSL aged 18–70 years with WHO performance status 0–3 was randomized between treatment with MBVP chemotherapy with or without rituximab, followed by high-dose cytarabine consolidation in responding patients, and reduced-dose WBRT in patients aged ≤ 60 years. Event-free survival was the primary endpoint. Overall survival rate, neurocognitive functioning (NCF), and health-related quality of life (HRQoL) were additionally assessed, with the IPCG test battery, EORTC QLQ-C30 and QLQ-BN20 questionnaires, respectively. Results For event-free survival, the hazard ratio was 0.85, 95% CI 0.61–1.18, P = .33. Overall survival rate at 5 years for MBVP and R-MBVP was 49% (39–59) and 53% (43–63) respectively. In total, 64 patients died in the MBVP arm and 55 in the R-MBVP arm, of which 69% were due to PCNSL. At the group level, all domains of NCF and HRQoL improved to a clinically relevant extent after treatment initiation, and remained stable thereafter up to 60 months of follow-up, except for motor speed which deteriorated between 24 and 60 months. Although fatigue improved initially, high levels persisted in the long term. Conclusions Long-term follow-up confirms the lack of added value of rituximab in addition to MBVP and HD-cytarabine for PCNSL.
Ubiquitin‐specific protease 22 promotes tumorigenesis and progression by an FKBP12/mTORC1/autophagy positive feedback loop in hepatocellular carcinoma
Authors: Qianwei Ye, Wei Zhou, Shengjun Xu, Qingyang Que, Qifan Zhan, Lincheng Zhang, Shusen Zheng, Sunbin Ling, Xiao Xu
Journal: MedComm (2023)

Ubiquitin-specific protease 22 (USP22) has been identified as a potential marker for cancer stem cells in hepatocellular carcinoma (HCC). It can promote HCC stemness, which is considered a driver of tumorigenesis. Here, we sought to determine the role of USP22 in tumorigenesis, elucidate its underlying mechanism, and explore its therapeutic significance in HCC. As a result, we found that tissue-specific Usp22 overexpression accelerated tumorigenesis, whereas Usp22 ablation decelerated it in a c-Myc/NRasGV12-induced HCC mouse model and that the mammalian target of rapamycin complex 1 (mTORC1) pathway was activated downstream. USP22 overexpression resulted in increased tumorigenic properties that were reversed by rapamycin in vitro and in vivo. In addition, USP22 activated mTORC1 by deubiquitinating FK506-binding protein 12 (FKBP12) and activated mTORC1, in turn, further stabilizing USP22 by inhibiting autophagic degradation. Clinically, HCC patients with high USP22 expression tend to benefit from mTOR inhibitors after liver transplantation (LT). Our results revealed that USP22 promoted tumorigenesis and progression via an FKBP12/mTORC1/autophagy positive feedback loop in HCC. Clinically, USP22 may be an effective biomarker for selecting eligible recipients with HCC for anti-mTOR-based therapy after LT.
Synergistic Activity of Adefovir Dipivoxil and Venetoclax to Target the Bioenergetic Metabolism of Acute Myeloid Leukemia
Authors: Xubo Gong, Yi Zhang, Ying-Chieh Chen, Dandan Zhao, Yongfang Xu, Xin He, Fang Chen, Lei Zhang, Lianjun Zhang, Katrina Estrella, Melissa Valerio, Lucy Y. Ghoda, Le Xuan Truong Nguyen, Ya-Huei Kuo, Weiwei Liu, Zhihua Tao, Guido Marcucci, Bin Zhang
Journal: Blood (2023)
Cyclical endometrial repair and regeneration: Molecular mechanisms, diseases, and therapeutic interventions
Authors: Xulin Hu, Haoming Wu, Xin Yong, Yao Wang, Shuhao Yang, Diyi Fan, Yibo Xiao, Lanyu Che, Kun Shi, Kainan Li, Chengdong Xiong, Huili Zhu, Zhiyong Qian
Journal: MedComm (2023)

Abstract The endometrium is a unique human tissue with an extraordinary ability to undergo a hormone‐regulated cycle encompassing shedding, bleeding, scarless repair, and regeneration throughout the female reproductive cycle. The cyclical repair and regeneration of the endometrium manifest as changes in endometrial epithelialization, glandular regeneration, and vascularization. The mechanisms encompass inflammation, coagulation, and fibrinolytic system balance. However, specific conditions such as endometriosis or TCRA treatment can disrupt the process of cyclical endometrial repair and regeneration. There is uncertainty about traditional clinical treatments' efficacy and side effects, and finding new therapeutic interventions is essential. Researchers have made substantial progress in the perspective of regenerative medicine toward maintaining cyclical endometrial repair and regeneration in recent years. Such progress encompasses the integration of biomaterials, tissue‐engineered scaffolds, stem cell therapies, and 3D printing. This review analyzes the mechanisms, diseases, and interventions associated with cyclical endometrial repair and regeneration. The review discusses the advantages and disadvantages of the regenerative interventions currently employed in clinical practice. Additionally, it highlights the significant advantages of regenerative medicine in this domain. Finally, we review stem cells and biologics among the available interventions in regenerative medicine, providing insights into future therapeutic strategies.
A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
Authors: Andrew T. Kuykendall, Somedeb Ball, Jason Gotlib, Cecilia Y. Arana Yi, Tsewang Tashi, Raajit K. Rampal, Daniel J. DeAngelo, Virginia O. Volpe, Kristen Marie Pettit, Rami S. Komrokji, Eric Padron
Journal: Blood (2023)
CYT-338 NK Cell Engager Mutispecific Antibody Engagement of NKp46 Activation Receptor Overcomes Anti-CD38 Mab Mediated Fratricide of NK Cells and Accords Enhanced Cancer Immunotherapy
Authors: Vishal Khairnar, Liang Lin, Hao-Ming Chang, Sourindra Maiti, Solgalim Diaz, Ofer Mandelboim, Tariq Mughal, Dan Chiche, Elisabetta Burchi, Armand Bensussan, Jean Kadouche, Ola Landgren, Dickran Kazandjian, Armin Rath, Daniel Teper, Wei Li, Antonio Arulanandam
Journal: Blood (2023)
Correlation between Clinical Diagnosis and Histopathological Findings of Liver Dysfunction after Allogeneic-HSCT
Authors: Ka Young Kim, Jung Yeon Lee, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong-Wook Lee, Jae-Ho Yoon
Journal: Blood (2023)
Loss of Function of SETD2 Tumor Suppressor in Chronic Myeloid Leukemia (CML) Progenitors Fosters Genomic Instability and Enhances Clonogenic Potential
Authors: Sara De Santis, Manuela Mancini, Cecilia Monaldi, Gabriele Gugliotta, Samantha Bruno, Fausto Castagnetti, Miriam Iezza, Marco Cerrano, Alessandra Iurlo, Sara Galimberti, Serena Balducci, Fabio Stagno, Michele Cavo, Simona Soverini
Journal: Blood (2023)
Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)
Authors: Imran Ahmad, Samia Harbi, Raynier Devillier, Cristina Castilla-Llorente, Marie Robin, Micha Srour, Jacques-Olivier Bay, Patrice Ceballos, Stéphanie Nguyen-Quoc, Édouard Forcade, Claude-Éric Bulabois, Amandine Charbonnier, Pascal Turlure, Sylvain Chantepie, Sébastien Maury, Michael Loschi, Hélène Labussière-Wallet, Tony Marchand, Marianne Schwarz, Ambroise Marçais, Ana Berceanu, Étienne Daguindau, Patrice Chevallier, Anne Huynh, Mohamad Mohty, Remy Dulery, Johan Maertens, Xavier Poiré, Natacha Maillard, Marie-Thérèse Rubio, Gaëlle Guillerm, Yves Chalandon, Anne-Lise Ménard, Jérôme Cornillon
Journal: Blood (2023)
Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody
Authors: Iryna Dekhtiarenko, Iva Lelios, Wolfgang Jacob, Meike Schneider, Martin Weisser, Carmelo Carlo-Stella, Salomon Manier, Simon J. Harrison, Rakesh Popat, Anna Caroline Hasselbalch Riley, Ann-Marie E. Bröske
Journal: Blood (2023)
Red Blood Cell Transfusion Dependence Is Associated with Greater Healthcare Resource Utilization, Higher Medical Cost, and Poorer Prognosis in Patients with Lower-Risk Myelodysplastic Syndromes: A 28-Year Retrospective Observation Study Result
Authors: Jun Ho Jang, Ji-Hyun Kim, Kyungah Lee, Eugene Kim, Hyojin Kim, Fangyuan Wang
Journal: Blood (2023)
Clinicopathologic Features and Survival Outcomes of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) of the Urothelial Organs (Urologic MALT Lymphoma): The Mayo Clinic Experience (2013-2022)
Authors: Ahmad Ghorab, Firas Baidoun, Osama Mosalem, Karan Seegobin, Muhamad Alhaj Moustafa, Han Tun
Journal: Blood (2023)
SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: SI101-02 First-in-Human Phase I/II
Authors: Raynier Devillier, Regis Peffault De Latour, Patrice Chevallier, Anne Huynh, Patrizia Chiusolo, Aurelie Bauquet, Laura Simons, Pierre Heimendinger, Olivier Negre, Shabi Soheili, Juliette Paillet, Isabelle Andre, Sebastien Oster, Marina Cavazzana, Frédéric François Lehmann, Fabio Ciceri
Journal: Blood (2023)
Comparative Analysis of Patient Characteristics, BTK Treatment, and Treatment Outcomes in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Cross-National Study between the United States and China
Authors: Yin Liu, Yanfei Chen, Yue Xiao, Ruijian Huang, Feng Jiang, Jifang Zhou
Journal: Blood (2023)
Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features
Authors: Hussain Alcassab, Koji Sasaki, Danielle E. Hammond, Alex Bataller, David B Beck, Tapan M. Kadia, Guillermo Montalban-Bravo, Kelly S. Chien, L. Jeffrey Medeiros, Hagop Kantarjian, Awdesh Kalia, Manjunath Nimmakayalu, Carlos E. Bueso-Ramos, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna
Journal: Blood (2023)
Clinical and Economic Burden of Illness in Patients with Persistent or Chronic Primary Immune Thrombocytopenia Treated with TPO-Ras and Rituximab
Authors: David J Kuter, Siddhi Umarje, Imene Gouia, Matias Cordoba, Brad Ward, Ines Hemim, Natalia Petruski-Ivleva
Journal: Blood (2023)
A Public Neoantigen Produced By the SF3B1 K700E Mutation Is a <i>Bona Fide</i> T Cell Target in AML/MDS
Authors: Noah J Tubo, Duncheng Wang, Qiuming He, Yibin Chen, Ho Ngai, Yanqing Huang, Celine Kerros, Xizeng Mao, Shoudan Liang, Hong He, Gheath Alatrash, Priya Koppikar, Jeffrey J. Molldrem
Journal: Blood (2023)
The Prevalence and Mutational Spectrum of Clonal Hematopoiesis in Diverse Populations in New York City
Authors: Varun Gupta, Mariko Isshiki, Anna Skwarska, Kith Pradhan, Amit K. Verma, Marina Y. Konopleva, Aditi Shastri, Srilakshmi Raj
Journal: Blood (2023)
New Insights into Hematopoietic Redefinition and New Paradigms in Hematopoietic Hierarchy Roadmap
Authors: Lipeng Chen, Qing Sun, Jihao Zhou, Guoqiang Li, Qijun Huang, Xiao Qiu, Jiahe Zhang, Chun Feng, Lina Hu, Yongjian Yue
Journal: Blood (2023)
Evaluation of Efficacy and Safety of Nivolumab in Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma at King Abdulaziz Medical City-Jeddah/the Kingdom of Saudi Arabia Experience
Authors: Amani Reda Alsafi, Majed Alahmadi, Ahmed Absi, Ahmad S. Alsaeed, Sameer Alamoudi, Ihab Hemaidi, Walaa Rajkhan, Manar Khalil, Saleem Dadah, Ahmed Said Higazi, Mubarak Almansour, Roula Almufti
Journal: Blood (2023)
Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax
Authors: Onyee Chan, Luis E. Aguirre, Mary Burke, Najla H Al Ali, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Jeffrey Lancet, Rami S. Komrokji, David A Sallman
Journal: Blood (2023)
Europeanpediatric Acute Leukemia (EuPAL) Registry
Authors: Katarzyna Majstrowicz, Katharina Waack, Evangelia Antoniou, Naghmeh Niktoreh, Gwen Nichols, Laura Di Laurenzio, Michele S. Redell, Todd Cooper, E. Anders Kolb, Sarah K. Tasian, Franco Locatelli, C. Michel Zwaan, Dirk Reinhardt
Journal: Blood (2023)
The Promising Third-Generation TKI Olverembatinib in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed/Refractory Disease
Authors: Weiyang Liu, Cheng Wang, Sijie Tang, Jiayi Ren, Lijun Peng, Yongmei Zhu, Xiangqin Weng, Wanyan Ouyang, Jie Xu, Yuanfang Liu, Weiping Zhang, Jin Wang, Jian-Qing Mi
Journal: Blood (2023)
Radiotherapy As an Effective Bridge for Relapsed/Refractory Secondary CNS Lymphoma
Authors: Gustav Cederquist, Kathryn Tringale, Carla Hajj, Harper Hubbeling, Jennifer Ma, Alexandra Dreyfuss, Beatrice Fregonese, Gilles Salles, Christian Grommes, Michael Scordo, Lorenzo Falchi, Joachim Yahalom, Brandon S. Imber
Journal: Blood (2023)
Post-Transplant Maintenance in AML and MDS Patients Undergoing Non-Myeloablative Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide
Authors: Lan Lei, Asad Bashey, Scott R. Solomon, Lawrence Morris, H Kent Holland, Melhem M. Solh, Katelin C Jackson, Xu Zhang, Lizamarie Bachier Rodriguez
Journal: Blood (2023)
<i>UBA1</i> Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes
Authors: Maria Sirenko, Elsa Bernard, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E Arango Ossa, Olivier Kosmider, Robert Hasserjian, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Carmelo Gurnari, Matilde Yung Follo, Felicitas Thol, Lurdes Zamora, Andrea Pellagatti, Harold K Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio P. S. Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Sole, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B Beck, Eva Hellstrom Lindberg, Elli Papaemmanuil
Journal: Blood (2023)
Impact of Early Anti-Cytomegalovirus Therapy on the Incidence of Chronic Graft-Versus-Host Disease
Authors: Kotaro Miyao, Makoto Murata, Tetsuya Nishida, Yukiyasu Ozawa, Naoyuki Uchida, Takahiro Fukuda, Noriko Doki, Tetsuya Eto, Toshiro Kawakita, Yasuo Mori, Satoru Takada, Hiroyuki Ohigashi, Masatsugu Tanaka, Yoshinobu Kanda, Ken-ichi Matsuoka, Fumihiko Ishimaru, Yoshiko Atsuta, Junya Kanda, Seitaro Terakura
Journal: Blood (2023)
Survival of Hematopoietic Stem Cell Transplantation in the National Institute of Neoplastic Diseases, Lima-Perú between 2012 to 2022: 10 Years of Experience
Authors: Shirley Quintana, Naty López Córdova, Lourdes ISABEL Lopez Chavez, Cindy Alcarraz, Victor IVAN Mallma Soto, Monica Calderon, Sharon Chavez, Tatiana Vidaurre, Claudio Flores, Jule F Vasquez
Journal: Blood (2023)
Eliminating Racial Disparities Among Transplant Patients in Multiple Myeloma after Referral to a Tertiary Center
Authors: Shreya Desai, Meaghan Standridge, Danielle Bradshaw, Mohammad Mian, Ayushi Chauhan, Amany R. Keruakous, Locke Johnson Bryan, Jorge Cortes, Anand Jillella, Vamsi K. Kota
Journal: Blood (2023)
Characterization of Niche Cells and Signals Regulating Stepwise Embryonic Hematopoiesis Using Slide-Seq and Merfish Spatial Transcriptomics
Authors: Xinjian Mao, Ning Zhang, Xi He, Kate Hall, Kaitlyn Petentler, Allison Scott, Seth Malloy, Jeff Haug, Hua Li, Anoja Perera, Jay Unruh, Brian Slaughter, Nancy Speck, Linheng Li
Journal: Blood (2023)
Real-World Treatment Patterns Among Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Who Initiated an Asparaginase Treatment after the Approval of Recombinant <i>Erwinia</i> (Rylaze)
Authors: Luke Maese, Helen Latimer, Katherine Nerney, Yanyan Cao, Melisa Stricherz, Roderick Murphy, Abby Chen, Wenqing Su, Weiyi Ni, Patricia Prince, Elizabeth Poole
Journal: Blood (2023)
Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation Using Busulfan/Cyclophosphamide and Melphalan or Thiotepa As Conditioning Regimen in 37 Patients with Acute Megakaryoblastic Leukemia
Authors: Fei Pan, Hongxing Liu, Guanlan Yue, Kang Gao, Kun Wang, Huili Zhu, Yujie Wang, Zheren Wang, Zhijie Wei
Journal: Blood (2023)
Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients
Authors: Gregorio Barila, Angela Grassi, Concetta Conticello, Roberto Mina, Chiara Marcon, Francesca Fazio, Claudio Salvatore Cartia, Martina Tinelli, Maria Livia Del Giudice, Sofia Pilerci, Angelo Belotti, Anna Pascarella, Mariantonietta Tafuri, Serena Rocchi, Nicola Sgherza, Giuseppe Mele, Edoardo Scomazzon, Massimo Gentile, Marika Porrazzo, Norbert Pescosta, Anna Furlan, Massimiliano Arangio Febbo, Cristina Clissa, Andrea Casson, Rossella Ribolla, Antonio Maroccia, Chiara Lisi, Enrica Antonia Martino, Ombretta Annibali, Gabriele Buda, Elisabetta Antonioli, Silvia Mangiacavalli, Alberto Tosetto, Pellegrino Musto, Francesca Gay, Elena Zamagni, Maria Teresa Petrucci, Francesco Di Raimondo, Francesca Patriarca, Renato Zambello
Journal: Blood (2023)
Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia in China: A Retrospective Analysis Using a Real-World Database
Authors: Yin Liu, Yanfei Chen, Yue Xiao, Ruijian Huang, Feng Jiang, Shuhua Yi, Jifang Zhou
Journal: Blood (2023)
Daprodustat, a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, Improves Hematological Insufficiency without Progression of Myelodysplastic Syndrome with Chronic Kidney Disease
Authors: Ryujiro Hara, Toshihiko Kitahara, Hiroki Numata, Shigeki Watanabe, Eri Kikkawa, Makoto Onizuka, Hiroshi Kawada
Journal: Blood (2023)
High Grade B-Cell Lymphoma with 11q Aberration Is Not a Rare Event in HIV-Associated Lymphoma
Authors: Amy Chadburn, Paul Rubinstein, Ethel Cesarman, Swarna Gogineni, MIn Yang, Maneeza Bilal, Nadine Demko, Ivo N. Sah Bander, Chandler Sy, Victoria Alagiozian-Angelova, Liming Bao
Journal: Blood (2023)
Day 100 Inhibitory KIR2DL2 and Activating NKp30 Natural Killer Cell Receptors Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas
Authors: Luis Porrata, Stephen M Ansell, Ivana Micallef, Patrick B Johnston, J. C. C Villasboas, Jonas Paludo, Urshila Durani, Svetomir Markovic
Journal: Blood (2023)
Effect of Ivospemin and Difluoromethylornithine Polyamine Inhibitors on Viability of Myeloma Cell Lines
Authors: Abdur Rehman, Lubna Rehman, Krish Devnani, Cao Cuong Le, Chun-Yen Lin, Xiayoun Cheng, Fuliang Chu, Jinsheng Weng, Jingwei Liu, Sridevi Patchva, Shao-Qing Kuang, Jingjing Cao, Matthew Richard, Elizabeth Bruckheimer, Sattva S. Neelapu, Neeraj Y. Saini
Journal: Blood (2023)